111 related articles for article (PubMed ID: 38864912)
1. Cancer-associated fibroblasts: heterogeneity and their role in the tumor immune response.
Xiao Y; Wang Z; Gu M; Wei P; Wang X; Li W
Clin Exp Med; 2024 Jun; 24(1):126. PubMed ID: 38864912
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling.
Chen PY; Wei WF; Wu HZ; Fan LS; Wang W
Front Immunol; 2021; 12():671595. PubMed ID: 34305902
[TBL] [Abstract][Full Text] [Related]
3. The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.
Piper M; Mueller AC; Karam SD
Mol Carcinog; 2020 Jul; 59(7):754-765. PubMed ID: 32363633
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated fibroblasts: Just on the opposite side of antitumour immunity?
Guo S; Yuan J; Meng X; Feng X; Ma D; Han Y; Li K
Int Immunopharmacol; 2023 Sep; 122():110601. PubMed ID: 37418988
[TBL] [Abstract][Full Text] [Related]
7. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials.
Zhang H; Yue X; Chen Z; Liu C; Wu W; Zhang N; Liu Z; Yang L; Jiang Q; Cheng Q; Luo P; Liu G
Mol Cancer; 2023 Oct; 22(1):159. PubMed ID: 37784082
[TBL] [Abstract][Full Text] [Related]
8. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
[TBL] [Abstract][Full Text] [Related]
9. Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.
De Jaeghere EA; Denys HG; De Wever O
Trends Cancer; 2019 Nov; 5(11):704-723. PubMed ID: 31735289
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer.
Yamauchi M; Gibbons DL; Zong C; Fradette JJ; Bota-Rabassedas N; Kurie JM
Matrix Biol; 2020 Sep; 91-92():8-18. PubMed ID: 32442601
[TBL] [Abstract][Full Text] [Related]
11. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment.
Monteran L; Erez N
Front Immunol; 2019; 10():1835. PubMed ID: 31428105
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
13. Exploiting the STAT3 Nexus in Cancer-Associated Fibroblasts to Improve Cancer Therapy.
Allam A; Yakou M; Pang L; Ernst M; Huynh J
Front Immunol; 2021; 12():767939. PubMed ID: 34858425
[TBL] [Abstract][Full Text] [Related]
14. Cancer-Associated Fibroblasts Affect Intratumoral CD8
Kato T; Noma K; Ohara T; Kashima H; Katsura Y; Sato H; Komoto S; Katsube R; Ninomiya T; Tazawa H; Shirakawa Y; Fujiwara T
Clin Cancer Res; 2018 Oct; 24(19):4820-4833. PubMed ID: 29921731
[No Abstract] [Full Text] [Related]
15. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma.
Xiang H; Ramil CP; Hai J; Zhang C; Wang H; Watkins AA; Afshar R; Georgiev P; Sze MA; Song XS; Curran PJ; Cheng M; Miller JR; Sun D; Loboda A; Jia Y; Moy LY; Chi A; Brandish PE
Cancer Immunol Res; 2020 Apr; 8(4):436-450. PubMed ID: 32075803
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies.
Mhaidly R; Mechta-Grigoriou F
Semin Immunol; 2020 Apr; 48():101417. PubMed ID: 33077325
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
Ravichandra A; Bhattacharjee S; Affò S
Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
[TBL] [Abstract][Full Text] [Related]
18. The Origin, Differentiation, and Functions of Cancer-Associated Fibroblasts in Gastrointestinal Cancer.
Huang J; Tsang WY; Li ZH; Guan XY
Cell Mol Gastroenterol Hepatol; 2023; 16(4):503-511. PubMed ID: 37451403
[TBL] [Abstract][Full Text] [Related]
19. CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage.
Wei R; Song J; Pan H; Liu X; Gao J
Oncoimmunology; 2024; 13(1):2352179. PubMed ID: 38746869
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Associated Fibroblasts in Gastrointestinal Cancers: Unveiling Their Dynamic Roles in the Tumor Microenvironment.
Al-Bzour NN; Al-Bzour AN; Ababneh OE; Al-Jezawi MM; Saeed A; Saeed A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
